Printer Friendly

United States : ASTELLAS needs US FDA approval for tacrolimus ER capsules.

As per the reports, Astellas Pharma US, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc. has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for tacrolimus extended release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients. Tacrolimus extended release capsules are a once daily formulation of calcineurin-inhibitor immunosuppressant tacrolimus.

Astellas was granted marketing approval for tacrolimus extended release capsules under the trade name Advagraf in Europe in 2007 and under the trade name Graceptor in Japan in 2008. In total, tacrolimus extended release capsules have been approved for use in 69 countries resulting in more than 140,000 patient years of experience.

Roy First, MD, Astellas Global Therapeutic Area Head for Transplantation said, There remains a large unmet treatment need for transplant recipients who have a difficult time controlling their immunosuppression drug levels with existing products. Astellas believes tacrolimus extended release capsules, given the efficacy, safety profile and unique dosing schedule, offer a potentially promising treatment option for recipients.

2012 Al Bawaba (Albawaba.com)

Provided by Syndigate.info an Albawaba.com company
COPYRIGHT 2012 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Geographic Code:9JAPA
Date:Sep 27, 2012
Words:190
Previous Article:United States : Retail Properties of America, Inc. Recommends Rejection of Mini-Tender Offer by LAPIS Investment Business Trust.
Next Article:United States : GABON uses biometric technology for civil registry.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters